Gritstone Oncology, Inc. announced that it is advancing its bispecific antibody (BiSAb) program under the direction of newly appointed vice president of Antibody Therapeutics, Jonah Rainey, Ph.D. Jonah Rainey, Ph.D., Vice President of Antibody Therapeutics Dr. Jonah Rainey joined Gritstone in 2018 to lead the bispecific antibody program. He has been actively engaged in discovery, research, and development of BiSAb for 12 years. He is an inventor on several patents and applications describing novel bispecific platforms, as well as current clinical candidates that exploit these platforms. Dr. Rainey led or had major contributions to research and early development of at least three current clinical candidates in phase 1 and 2, and led many additional advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas.